GFM
ELVN icon

GF Fund Management’s Enliven Therapeutics ELVN Stock Holding History

GF Fund Management’s Portfolio ELVN Stock Details ELVN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$52.3K Buy
1,333
+168
+14% +$4.65K ﹤0.01% 393
2025
Q4 		$17.9K Sell
1,165
-109
-9% -$2.17K ﹤0.01% 519
2025
Q3 		$26.1K Buy
1,274
+23
+2% +$464 ﹤0.01% 459
2025
Q2 		$25.1K Hold
1,251
– – ﹤0.01% 477
2025
Q1 		$24.6K Buy
1,251
+225
+22% +$4.84K ﹤0.01% 479
2024
Q4 		$23.1K Buy
+1,026
New +$26.6K ﹤0.01% 460

Other funds holding ELVN

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return